Loading market information…
JPX · 2342.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Trans Genic Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Trans Genic Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilation of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
